About ReveraGen
ReveraGen is a company based in Rockville (United States) founded in 2008 by Kanneboyina Nagaraju.. ReveraGen offers products and services including Vamorolone. ReveraGen operates in a competitive market with competitors including Alnylam, Ultragenyx, BioMarin Pharmaceutical, Mirum Pharmaceuticals and Homology Medicines, among others.
- Headquarter Rockville, United States
- Founders Kanneboyina Nagaraju
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Reveragen Biopharma, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
$1.2 M (USD), Grant
Sep 27, 2021
-
Investors
NIH
& 9 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ReveraGen
ReveraGen offers a comprehensive portfolio of products and services, including Vamorolone. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Drug designed to treat Duchenne Muscular Dystrophy with improved safety.
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of ReveraGen
- Total Funding Total Funding
- Total Rounds 19
- Last Round Grant — $1.2M
-
First Round
First Round
(16 Sep 2010)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2021 | Amount | Grant - ReveraGen | Valuation |
investors |
|
| Sep, 2021 | Amount | Grant - ReveraGen | Valuation |
investors |
|
| Nov, 2020 | Amount | Grant - ReveraGen | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in ReveraGen
ReveraGen has secured backing from 10 investors, including institutional investors. Prominent investors backing the company include NIH, HHS and European Union. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
The U.S. Food and Drug Administration is tasked with regulating food, drugs, and medical products.
|
Founded Year | Domain | Location | |
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location | |
|
Drug discovery services are provided to the biopharma sector.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by ReveraGen
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - ReveraGen
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Reveragen Comparisons
Competitors of ReveraGen
ReveraGen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alnylam, Ultragenyx, BioMarin Pharmaceutical, Mirum Pharmaceuticals and Homology Medicines, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics are developed for rare diseases treatment.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for rare genetic diseases
|
|
| domain | founded_year | HQ Location |
Orally deliverable bradykinin B2 antagonists are developed for hereditary angioedema.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Reveragen
Frequently Asked Questions about ReveraGen
When was ReveraGen founded?
ReveraGen was founded in 2008 and raised its 1st funding round 2 years after it was founded.
Where is ReveraGen located?
ReveraGen is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.
Who is the current CEO of ReveraGen?
Eric Hoffman is the current CEO of ReveraGen.
What does ReveraGen do?
ReveraGen was founded in 2008 in Rockville, United States, as a drug development company focused on neuromuscular diseases. Proprietary therapeutic products, including the lead candidate Vamorolonea steroidal anti-inflammatoryare discovered and developed for conditions such as Duchenne muscular dystrophy. Operations center on advancing treatments through clinical stages, with emphasis on innovative steroid formulations for patient care in the biotechnology sector.
Who are the top competitors of ReveraGen?
ReveraGen's top competitors include Alnylam, UniQure and BioMarin Pharmaceutical.
What products or services does ReveraGen offer?
ReveraGen offers Vamorolone.
Who are ReveraGen's investors?
ReveraGen has 10 investors. Key investors include NIH, HHS, European Union, U.S. Food and Drug Administration, and Duchenne UK.